Centocor's ReoPro/Stent Combination Studies Could Be Attractive To J&J
This article was originally published in The Gray Sheet
Executive Summary
Centocor's $250 mil. investment in studies to demonstrate the efficacy of its drug ReoPro in combination with coronary stents in percutaneous coronary interventions could be attractive to Johnson & Johnson, which reportedly has been in discussions to acquire the biotech firm.
You may also be interested in...
J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales
Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.
J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales
Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.
Abbott Sews Up Puncture Seal Deal As Perclose Stock Falls On Recall Rumors
Abbott's July 8 acquisition of Perclose in a stock swap valued at about $680 mil. portends the firm's long-term strategy to expand its interventional cardiology presence at a tempered pace.